Vogenx

IPO
Biotech

BlossomHill, Latigo outshine IPO expectations

Blossom Hill Therapeutics and Latigo Biotherapeutics each raised at least 30% more than expected in their respective IPOs.
Will Maddox Aug 7, 2026 11:10am
IPO initial public offering

Attovia, Braveheart and Vogenx seek more than $500M via IPOs

Jul 30, 2026 8:57am
IPO initial public offering Wall Street

Vogenx joins the IPO queue to fund phase 2-stage metabolic drug

Jul 16, 2026 5:19am